FDA Extends Review Deadline For Ilex' Clofarabine

Ilex submits data on 14 additional patients with acute lymphoblastic and acute myeloid leukemia to FDA, extending the user fee date by three months to Dec. 30. The company completed the original rolling NDA March 29.